Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Dec 12:2:14.
doi: 10.1186/1471-2490-2-14. Epub 2002 Dec 12.

Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials

Jayne E Edwards  1 , R Andrew Moore
Affiliations

Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials

Jayne E Edwards et al. BMC Urol. .

Abstract

Background: Benign prostatic hyperplasia affects older men. This systematic review determined efficacy and adverse effects of finasteride.

Review methods: PubMed, the Cochrane Library, reference lists of reports, and reviews were searched for randomised, double-blind trials of finasteride in benign prostatic hyperplasia. Outcomes included symptom score, urinary flow rate, prostate volume, discontinuation, and adverse effects. Relative risk and NNT or NNH were calculated for dichotomous data. Sensitivity analyses assessed influences of baseline symptom severity, initial prostate volume, a dominating trial, and previous interventions.

Results: Three trials had active controls and 19 had placebo. In placebo-controlled trials, 8820 patients received finasteride 5 mg and 5909 placebo over 3-48 months. Over 48 months finasteride produced greater improvements in total symptom score, maximum urinary flow rate, and prostate volume. Significantly more sexual dysfunction, impotence, ejaculation disorder and decreased libido occurred with finasteride at 12 months; the NNH for any sexual dysfunction at 12 months was 14. Significantly fewer men treated with finasteride experienced acute retention or had surgery at 24 or 48 months than with placebo; at 12 months the NNT was 49 (31 to 112) to avoid one acute urinary retention and 31 (21 to 61) to avoid one surgery. Sensitivity analyses showed benefit with finasteride 5 mg to be constant irrespective of the initial prostate volume.

Conclusions: Information from many patients in studies of high quality showed beneficial effects of finasteride in terms of symptoms, flow rate and prostate volume. More utility would result if patient centred outcomes were reported in dichotomous form.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Total symptom scores using the American Urological Association scale (0–35).
Figure 2
Figure 2
Maximum urinary flow rate over time.
Figure 3
Figure 3
Prostate volume over time.
Figure 4
Figure 4
Effect of initial prostate volume – Replication of the analysis by Boyle and colleagues.
Figure 5
Figure 5
Effect of initial prostate volume – finasteride.
Figure 6
Figure 6
Effect of initial prostate volume – placebo.
See this image and copyright information in PMC

References

    1. Nordling J, Hald T. BPH versus LUTS: reflections on lower urinary tract symptoms in search of a definition of clinical benign prostatic hyperplasia. European Urology Update Series. 1997;6:54–60.
    1. Simpson RJ. Benign prostatic hyperplasia. An overview of epidemiology and treatment. Primary Care in the New NHS. 2001. pp. 184–186.
    1. Lee AJ, Garraway WM, Simpson RJ, et al. The natural history of untreated lower urinary tract symptoms in middle-aged and elderly men over a period of five years. Eur Urol. 1998;34:325–332. doi: 10.1159/000019749. - DOI - PubMed
    1. Macdonald R, Ishani A, Rutks I, et al. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. BJU International. 1999;85:836–841. doi: 10.1046/j.1464-410x.2000.00365.x. - DOI - PubMed
    1. Clifford GM, Farmer RDT. Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur Urol. 2000;38:2–19. doi: 10.1159/000020246. - DOI - PubMed

Publication types

MeSH terms